Showing results (91-100 of 260) with videos related to

Sort By:
Pageof 26
Diagnostic Microbiology and Infectious Disease|October 11, 2014
A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant Staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast ItalyPiergiorgio Cojutti, Claudio Scarparo, Assunta Sartor, et al.
Microorganisms|January 23, 2024
Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin-Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot StudyMilo Gatti, Cecilia Bonazzetti, Renato Pascale, et al.
Antimicrobial Agents and Chemotherapy|February 29, 2012
Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapyFederico Pea, Piergiorgio Cojutti, Alberto Pagotto, et al.
Antimicrobial Agents and Chemotherapy|August 2, 2017
Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniaePiergiorgio Cojutti, Assunta Sartor, Elda Righi, et al.
Diagnostic Microbiology and Infectious Disease|March 21, 2007
Major role of levofloxacin in the treatment of a case of Listeria monocytogenes meningitisPierluigi Viale, Mario Furlanut, Francesco Cristini, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2013
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrationsPiergiorgio Cojutti, Anna Candoni, Erica Simeone, et al.
Antibiotics (Basel, Switzerland)|April 26, 2024
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAPMilo Gatti, Matteo Rinaldi, Tommaso Tonetti, et al.
Antibiotics (Basel, Switzerland)|November 24, 2023
Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative InfectionsMilo Gatti, Matteo Rinaldi, Cristiana Laici, et al.
Antibiotics (Basel, Switzerland)|October 27, 2023
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous HemodiafiltrationMilo Gatti, Matteo Rinaldi, Tommaso Tonetti, et al.
Antibiotics (Basel, Switzerland)|December 23, 2022
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired PneumoniaMilo Gatti, Maddalena Giannella, Matteo Rinaldi, et al.
Pageof 26